Other PHGDH inhibitors shown to reduce proliferation of serine addicted cancer (but remain as of yet untested in AML, MDS, or MPN) include the pro-drug BI-4924, PHGDH-Hit, NCT502, and NCT503 (78, 79). Here, PHGDH is linked to myeloproliferative disorder.